Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model

Figure 2

Anti-tumor effect in mouse CT26 colon adenocarcinoma model. Female BALB/c mice received i.v. injection of 2×105 CT26 cells in 100 μl of PBS. Treatment with 1×106 Adv-GFP-sFlt-1 infected BMSCs(, black rhombus), 1×106 Adv-GFP infected BMSCs (▪, black quadrilateral), 1×106 uninfected BMSCs (▲, black triangle) and 100 μl of 0.9% NaCl solution alone (, black circularity) were administered i.v. from tail vein. Treatment with sFlt-1-bearing BMSCs could decrease the number of and growth of surface metastases (Figure 2-A, D) and abolish the tumor burden by rendering the weight of lungs similar to that of normal mice (Figure 2-C). Mean numbers of lung tumor nodules in each group are shown (Figure 2-B). Values are plotted as means ± SEM (P < 0.05). The percentage of metastatic foci > 3 mm are marked as solid bars. A significant increase of survival rate in sFlt-1-bearing BMSCs treated mice, compared with the controls (Figure 2-E, P < 0.05. By log-rank test), was found in the tumor model.

Back to article page